Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

BACKGROUND: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CS...

Descripción completa

Detalles Bibliográficos
Autores principales: Karpova, Darja, Bräuninger, Susanne, Wiercinska, Eliza, Krämer, Ariane, Stock, Belinda, Graff, Jochen, Martin, Hans, Wach, Achim, Escot, Christophe, Douglas, Garry, Romagnoli, Barbara, Chevalier, Eric, Dembowski, Klaus, Hooftman, Leon, Bonig, Halvard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209880/
https://www.ncbi.nlm.nih.gov/pubmed/28049490
http://dx.doi.org/10.1186/s12967-016-1107-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209880/
https://www.ncbi.nlm.nih.gov/pubmed/28049490
http://dx.doi.org/10.1186/s12967-016-1107-2

Ejemplares similares